From: Multilayer network analysis of the drugs development cycle in the global pharmaceutical industry
\(G_3\): Ownership | ||||
---|---|---|---|---|
Index | Size | Country | Primary industry | Bow tie |
1: | 54845 | US (21.9) IND (9.0) CAN (6.4) CHN (5.7) AUS (5.2) GBR (5.2) JPN (5.1) | Asset management and custody banks (10.1) | IN (56.8) TE (42.2) |
7: | 644 | US (24.0) IND (10.3) CAN (6.2) AUS (5.9) JPN (5.4) | Asset management and custody banks (11.6) | IN (57.3) TE (41.1) |
6: | 532 | US (22.2) IND (8.3) CAN (7.5) AUS (6.2) JPN (5.8) CHN (5.1) | Asset management and custody banks (11.1) | IN (59.2) TE (39.7) |
3: | 525 | US (22.3) IND (9.2) CHN (5.9) CAN (5.9) | Asset management and custody banks (11.8) | IN (57.3) TE (41.9) |
12: | 403 | US (18.9) IND (10.4) CAN (7.7) AUS (5.7) | Asset management and custody banks (10.5) | IN (54.8) TE (44.2) |
16: | 364 | US (24.4) CAN (11.3) GBR (8.7) IND (8.7) | Asset management and custody banks (10.2) | IN (57.5) TE (41.2) |